NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free ELYM Stock Alerts $7.57 +0.48 (+6.77%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$6.66▼$7.7350-Day Range$2.54▼$7.0952-Week Range$2.34▼$7.80Volume936,273 shsAverage Volume627,617 shsMarket Capitalization$209.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Eliem Therapeutics alerts: Email Address Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesApril 26, 2024 | americanbankingnews.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Sees Significant Growth in Short InterestApril 23, 2024 | americanbankingnews.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%May 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | businesswire.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersApril 11, 2024 | globenewswire.comEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 5, 2024 | msn.comELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023March 6, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn SituationNovember 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTNovember 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.45% Return on Assets-30.43% Debt Debt-to-Equity RatioN/A Current Ratio38.92 Quick Ratio38.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book1.93Miscellaneous Outstanding Shares27,720,000Free Float26,832,000Market Cap$208.73 million OptionableNot Optionable Beta0.51 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOG1 TherapeuticsNASDAQ:GTHXVeruNASDAQ:VERULifecore BiomedicalNASDAQ:LFCRDesign TherapeuticsNASDAQ:DSGNView All CompetitorsInstitutional OwnershipBML Capital Management LLCBought 13,742 shares on 4/23/2024Ownership: 7.914%View All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed in 2024? Eliem Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ELYM shares have increased by 180.4% and is now trading at $7.57. View the best growth stocks for 2024 here. Are investors shorting Eliem Therapeutics? Eliem Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Based on an average daily volume of 665,800 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.3% of the company's shares are sold short. View Eliem Therapeutics' Short Interest. When is Eliem Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELYM earnings forecast. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Eliem Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (7.91%). How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubElon’s New Device is About to Shock the WorldInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
